The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate
Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Apr 23, 2007
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
Thirty Rheumatoid Arthritis patients currently treated with low dose methotrexate (MTX) will participate in this study. On the day of intake of methotrexate, the patients will receive 10 mg of MTX. Serum levels of MTX will be measured at time 0,30 ,90, 120 minutes, and after 12 and 24 hours.
Two weeks later, the patients will be recommended to take 100 mg aspirin/d during a week. The levels of MTX will be measured after a week of treatment in a way similar to a week before.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • RApatients treated with Methotrexate
- Exclusion Criteria:
- • Contraindication to aspirin
About Tel Aviv Sourasky Medical Center
Tel Aviv Sourasky Medical Center, a leading academic medical institution in Israel, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a multidisciplinary approach, the center integrates cutting-edge medical technology and evidence-based practices to enhance patient care and outcomes. Its robust infrastructure supports a diverse range of clinical studies, fostering collaboration among healthcare professionals, researchers, and industry partners. The center's dedication to research excellence and patient safety positions it as a key player in the global clinical research landscape, driving advancements in medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ori Elkayam, M.D
Principal Investigator
Tel Aviv Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials